INO - イノバロン・ホ―ルドング (Inovio Pharmaceuticals Inc.) イノバロン・ホ―ルドング

 INOのチャート


 INOの企業情報

symbol INO
会社名 Inovalon Holdings Inc (イノバロン・ホ―ルドング)
分野(sector) Health Care   ヘルスケア
産業(industry) Medical/Dental Instruments  
業種 バイオテクノロジ―_メディカルリサ―チ   IT・通信(IT_Communications)
概要 事業概要 アイノビオ・ファーマスーティカル(Inovio Pharmaceuticals Inc.)は癌と感染症の治療・予防に従事するデオキシリボ核酸(DNA)免疫療法とワクチンの開発を行う臨床段階の製薬会社である。同社のDNAベースの免疫療法はエレクトロポレーション送達デバイスと組み合わせて、標的疾患と戦う体内にある免疫応答、特にT細胞を生成する。同社はヒトパピローマウイルス(HPV)に起因する前癌・癌、インフルエンザ、前立腺癌、乳癌・肺癌・膵臓癌、C型肝炎ウイルス(HCV)、B型肝炎ウイルス(HBV)、ヒト免疫不全ウイルス(HIV)、エボラ、中東呼吸器症候群(MERS)及びジーファウイルスに対するSynCon免疫療法の臨床計画を完成する。同社は免疫療法プラットフォーム及びCELLECTRAエレクトロポレーション送達技術により、インビボ免疫応答を生じる前臨床・臨床段階製品のパイプラインを所有する。   イノバロン・ホ―ルドングは、米国の持株会社。医療にクラウドベ―スのデ―タ分析とデ―タ駆動介入プラットフォ―ムを組み合せた技術展開する。分析では、ケア、品質、デ―タの整合性、および財務実績のギャップを特定する。この差別組み合わせは、計画、病院、医師、患者、製薬会社や研究者のためのプラットフォ―ムを提供する。   INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with HPV. INOVIO is the first and only company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body via a proprietary smart device to produce a robust and tolerable immune response. INOVIO's lead immunotherapy candidate, VGX-3100, currently in Phase 3 trials for precancerous cervical dysplasia, cleared high-risk HPV-16 and/or HPV-18 in a Phase 2b clinical trial. High-risk HPV is responsible for 70% of cervical cancer, 91% of anal cancer, and 69% of vulvar cancer. Also in development are programs targeting HPV-related cancers and a rare HPV-related disease, recurrent respiratory papillomatosis (RRP); non-HPV-related cancers glioblastoma multiforme (GBM) and prostate cancer; as well as infectious disease DNA vaccine development programs in coronaviruses associated with COVID-19 diseases and MERS, Lassa fever, Ebola, and HIV. Partners and collaborators include Advaccine, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA)/Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND)/Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute (IVI), Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron, Richter-Helm BioLogics, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. INOVIO also is a proud recipient of 2020 Women on Boards 'W' designation recognizing companies with more than 20% women on their board of directors.
本社所在地 4321 Collington Road Bowie MD 20716 USA
代表者氏名 Jong Joseph Kim ジョン・ジョセフ・キム
代表者役職名 President Chief Executive Officer Director 社長兼最高経営責任者(CEO)
電話番号 +1 858-410-3134
設立年月日 41883
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 2480人
url www.inovalon.com
nasdaq_url https://www.nasdaq.com/symbol/ino
adr_tso
EBITDA EBITDA(百万ドル) -86.82719
終値(lastsale) 5.37
時価総額(marketcap) 491338003.95
時価総額 時価総額(百万ドル) 497.74280
売上高 売上高(百万ドル) 37.41017
企業価値(EV) 企業価値(EV)(百万ドル) 402.14780
当期純利益 当期純利益(百万ドル) -94.63071
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Inovio Pharmaceuticals Inc revenues decreased 16% to $26M. Net loss increased 20% to $39M. Revenues reflect Grants and miscellaneous revenue decrease of 99% to $95K Grants and miscellaneous revenue from af decrease from $1.7M to $0K Revenue under collaborative research and decrease of 49% to $208K. Higher net loss reflects General and administrative - Balancing v increase of 50% to $14.6M (expense).

 INOのテクニカル分析


 INOのニュース

   Global Hemagglutinin 5 Market 2021 Future Set to Massive Growth with High CAGR value | Market Players: Altravax, Inc., NewLink Genetics Corporation, Ilyang Pharmaceutical Co., Ltd, Inovio Pharmaceuticals, Inc., Vaxine Pty Ltd  2021/07/24 01:24:23 Jumbo News
The report on Global Hemagglutinin 5 Market has been provided by researchers for a detailed understanding of market performance over an estimated period of time set from 2021 to 2026. However, this report has introduced a brief overview to provide the reader with better information on this report. This brief description contains a basic definition []
   Global Microneedles and Needle-Free Injection Systems Market 2021 Future Set to Massive Growth with High CAGR value | Market Players: Inovio Pharmaceuticals, Valeritas, DAntonio Consultants International, 3M, Inolife Sciences, Medical International Technology, Micropoint Technologies, PharmaJet, Enesi Pharma, NanoPass Technologies, Nemaura Pharma  2021/07/23 20:37:08 Jumbo News
The report on Global Microneedles and Needle-Free Injection Systems Market has been provided by researchers for a detailed understanding of market performance over an estimated period of time set from 2021 to 2026. However, this report has introduced a brief overview to provide the reader with better information on this report. This brief description contains []
   Stock Buzzers: Inovio Pharmaceuticals, Inc. (NASDAQ:INO), Advaxis, Inc. (NASDAQ:ADXS)  2021/07/21 22:31:31 Stock Equity
Inovio Pharmaceuticals, Inc. (INO) with the stream of 1.51% also noticed, India Advaxis, Inc. (ADXS) encountered a rapid change of 1.16% in the last hour of Wednesdays trading session. Inovio The post Stock Buzzers: Inovio Pharmaceuticals, Inc. (NASDAQ:INO), Advaxis, Inc. (NASDAQ:ADXS) appeared first on Stocks Equity .
   Alarming Stock: Inovio Pharmaceuticals, Inc. (NASDAQ:INO), Titan Pharmaceuticals, Inc. (NASDAQ:TTNP)  2021/07/20 23:04:52 Stock Equity
Inovio Pharmaceuticals, Inc. (INO) with the stream of -4.99% also noticed, India Titan Pharmaceuticals, Inc. (TTNP) encountered a rapid change of 3.23% in the last hour of Tuesdays trading session. The post Alarming Stock: Inovio Pharmaceuticals, Inc. (NASDAQ:INO), Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) appeared first on Stocks Equity .
   Inovio Pharmaceuticals Stock Is Believed To Be Significantly Overvalued  2021/07/19 11:00:07 GuruFocus
Related Stocks: INO ,
   Inovio Pharmaceuticals, Inc. (NASDAQ:INO) CFO Peter Kies Sells 30,000 Shares of Stock  2021/01/16 12:18:41 Watchlist News
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) CFO Peter Kies sold 30,000 shares of the business’s stock in a transaction dated Friday, January 15th. The stock was sold at an average price of $10.02, for a total value of $300,600.00. Following the sale, the chief financial officer now owns 149,290 shares in the company, valued at approximately $1,495,885.80. […]
   Inovio Pharmaceuticals : VGX-3100 Demonstrates Positive Phase 2 Efficacy In Treatment of Precancerous Vulvar Dysplasia Caused by HPV-16/18 | MarketScreener  2021/01/06 13:01:35 MarketScreener
PLYMOUTH MEETING, Pa., Jan. 6, 2021 /PRNewswire/ -- INOVIO , a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious… | January 6, 2021
   Zika Virus Vaccines Market New Business Experts Ideas By Bharat Biotech International, GeneOne Life Science, Hawaii Biotech, Immunovaccine, NewLink Genetics, Inovio Pharmaceuticals, Cerus  2021/01/06 07:03:17 OpenPR
Zika Virus Vaccines Market Analysis to 2027 is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of Zika Virus Vaccines market with
   Inovio Expects To Begin Late-stage COVID-19 Vaccine Study In Second Quarter  2021/01/04 20:39:24 CNN-News18
Inovio Pharmaceuticals Inc expects to start a latestage U.S. study of its experimental COVID19 vaccine candidate in the second quarter of 2021, the drug developer's chief executive officer said on Monday.
   Inovio Partners With Advaccine To Make, Sell COVID-19 Vaccine In China  2021/01/04 16:33:34 CNN-News18
Advaccine Biopharmaceuticals Suzhou Co Ltd will manufacture and sell Inovio Pharmaceuticals Inc's COVID19 vaccine candidate in China, the companies said on Monday.
   Inovio Pharmaceuticals : VGX-3100 Demonstrates Positive Phase 2 Efficacy In Treatment of Precancerous Vulvar Dysplasia Caused by HPV-16/18 | MarketScreener  2021/01/06 13:01:35 MarketScreener
PLYMOUTH MEETING, Pa., Jan. 6, 2021 /PRNewswire/ -- INOVIO , a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious… | January 6, 2021
   Zika Virus Vaccines Market New Business Experts Ideas By Bharat Biotech International, GeneOne Life Science, Hawaii Biotech, Immunovaccine, NewLink Genetics, Inovio Pharmaceuticals, Cerus  2021/01/06 07:03:17 OpenPR
Zika Virus Vaccines Market Analysis to 2027 is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of Zika Virus Vaccines market with
   Inovio Expects To Begin Late-stage COVID-19 Vaccine Study In Second Quarter  2021/01/04 20:39:24 CNN-News18
Inovio Pharmaceuticals Inc expects to start a latestage U.S. study of its experimental COVID19 vaccine candidate in the second quarter of 2021, the drug developer's chief executive officer said on Monday.
   Inovio Partners With Advaccine To Make, Sell COVID-19 Vaccine In China  2021/01/04 16:33:34 CNN-News18
Advaccine Biopharmaceuticals Suzhou Co Ltd will manufacture and sell Inovio Pharmaceuticals Inc's COVID19 vaccine candidate in China, the companies said on Monday.
   Inovio Strikes $100M Coronavirus Vaccine Licensing Deal With China's Advaccine  2021/01/04 14:25:23 Benzinga
Shares of Inovio Pharmaceuticals Inc (NASDAQ: INO ), which is developing a DNA vaccine against the novel coronavirus, were advancing Monday. What Happened: Plymouth Meeting, Pennsylvania-based Inovio announced a collaboration and licensing agreement with China-based biotech Advaccine Biopharma to market its investigational vaccine INO-4800 in the Greater China region. The agreement provides Advaccine with the exclusive rights to develop, manufacture and commercialize INO-4800 within Greater China, which includes mainland China, Hong Kong, Macau and Taiwan. Advaccine will license its plasmid manufacturing process to Inovio for INO-4800 and other pipeline products. sublicense the rights to its manufacturing partners. Advaccine … Full story available on Benzinga.com

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 イノバロン・ホ―ルドング INO Inovio Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)